STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The STORM-trial consists of two parts. In the part I (dose escalation of Temsirolimus) the
primary objective is to establish a maximum tolerated dose of Temsirolimus in combination
with Rituximab and DHAP. Secondary objective is to prove ability to mobilize stem cells in
patients scheduled to high dose therapy.
In the part II (full target dose) the primary objective is to evaluate the ORR in patients
with relapsed diffuse large B cell lymphoma (DLBCL). The secondary objective is to evaluate
progression free survival (PFS), overall survival (OS) and Toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Mathias Witzens-Harig
Collaborators:
Charite University, Berlin, Germany Johann Wolfgang Goethe University Hospital Johannes Gutenberg University Mainz Ludwig-Maximilians - University of Munich Technische Universität München University Hospital Erlangen University Hospital Freiburg University Hospital Ulm